Loading…
← CockpitCompetitor Analysis › 300122.SZ Chongqing Zhifei Biological Products Co., Ltd. Class AOpen in the cockpit ↗

Chongqing Zhifei Biological Products Co., Ltd. Class A300122.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese vaccine company that develops its own vaccines and distributes Merck's HPV and other vaccines in China.

≈ A vaccine maker plus a Merck-vaccine distributor rolled into oneMomentum leader 97
Mkt cap
$5.28B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$73.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-64.5 pp
WACC 9.4%
Hurdle
+4 pp
Req g minus delivered
Next earnings
160 days
27 Apr 2027
Close · CNYCN¥14.86
1D+9.8%
1W+5.8%
1M+18.9%
3M+12.4%
6M-1.2%
YTD-21.2%
1Y-30.2%
ATR %3.8%
52w lowhigh33.0% off high

What Chongqing Zhifei Biological Products does

Chinese vaccine company that develops its own vaccines and distributes Merck's HPV and other vaccines in China.

Earns from two sources: distribution of imported vaccines, mainly Merck's, to China's provincial disease-control centres, which handle sales to vaccination clinics, and sales of vaccines it develops itself. Distribution has carried the business, leaving it reliant on one partner's supply; Merck paused Gardasil shipments to China in 2024 because demand was weak.

In one line: A vaccine maker plus a Merck-vaccine distributor rolled into one.

Products and services

  • Merck HPV vaccine distribution (Gardasil)
  • In-house vaccines (rabies, ACYW meningitis)
  • Tuberculosis vaccine pipeline

Customers

  • CDC/vaccination centers
  • Hospitals
  • Distributors

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Vaccines

What could go right

  • HPV vaccination demand
  • New vaccine approvals

What could go wrong

  • Dependence on Merck distribution agreement
  • Vaccine procurement pricing pressure

Moat: narrow (distribution, regulatory licence). Exclusive China distribution rights for Merck's Gardasil HPV vaccine plus its own vaccine portfolio.

Headquarters: Chongqing, China · Employees: 6,292

Named competitors

Chongqing Zhifei Biological Products at a glance

Size Chongqing Zhifei Biological Products (300122.SZ) is a China Health Care company (Biotechnology) with a market value of $5.28B, the 442nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.86 on 18 Nov 2026.

Performance Over six months the shares fell 1.2%, against -3.5% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue fell 27.8% over the last twelve months (peer median +3.6%); the operating margin is -210.4% (peer median -15.6%).

Valuation It trades at 5.3× enterprise value to sales against a peer median of 12.7× (5th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is -10%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 64.5 points below its cost of capital (9.4% WACC).

Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026300122.SZ 100Peer median 98
Six months, rebased to 100: Chongqing Zhifei Biological Products against the median of its 20 peers (local-currency closes).

Chongqing Zhifei Biological Products financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥7.87BCN¥8.92BCN¥26.0BCN¥52.8BCN¥38.1B
Revenue growth—-66%-51%+38%—
Gross profitCN¥848MCN¥575MCN¥6.94BCN¥14.0BCN¥12.7B
EBITDAn/a-CN¥16.7BCN¥2.66BCN¥9.59BCN¥9.03B
Net income-CN¥14.2B-CN¥14.7BCN¥1.97BCN¥8.11BCN¥7.54B
Free cash flowCN¥5.65BCN¥4.55B-CN¥5.43BCN¥7.86BCN¥536M
Capital expenditureCN¥451MCN¥619MCN¥1.20BCN¥1.13BCN¥1.45B
Total debtCN¥8.65BCN¥12.3BCN¥13.3BCN¥3.04BCN¥2.05B

Quarterly statements and history in the cockpit →

Chongqing Zhifei Biological Products competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%ANTHEMCAI300347COGTSRRKDNTHADPT002252ARWREWTX000661KOD1530603392IMVT6696AXSMCGONCRSPTXG300122.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Chongqing Zhifei Biological Products is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×500×1,000×1,500×ANTHEMCAI300347DNTH002252ARWR1530AXSMCGONCRSP300122.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Chongqing Zhifei Biological Products is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%ANTHEMCAI300347000661TXG300122.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Chongqing Zhifei Biological Products is the large dot.

Chongqing Zhifei Biological Products competitors and peer comparison

Head to head with its named competitors (300122.SZ vs 603392.SS vs 300601.SZ vs 300142.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Chongqing Zhifei Biological Products 300122.SZ$5.28B-1%-28%-210%5.3×-6.5%
Beijing Wantai Biological Pharmacy Enterprise 603392.SS$4.20B-43%+8%-35%12.7×n/a
Shenzhen Kangtai Biological Products 300601.SZ$1.86B-20%-9%6%4.9×22.7%
Walvax Biotechnology 300142.SZ$2.48B-26%-23%5%9.4×29.5%
Merck & MRK$340B+23%+5%18%5.7×8.3%

How Chongqing Zhifei Biological Products compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Chongqing Zhifei Biological Products against its 20 peers (data as of 18 Nov 2026)
Measure300122.SZPeer medianRank in peer set
1-month return+18.9%-3.4%2nd highest of 21
6-month return-1.2%-3.5%10th highest of 21
Distance from 52-week high-33.0%-31.9%10th lowest of 21
Revenue growth (TTM)-27.8%+3.6%3rd lowest of 15
Operating margin-210.4%-15.6%5th lowest of 16
EV / Sales5.3×12.7×5th cheapest of 16
Growth the price implies (Req g, 7 yrs)-6.5%32.4%least demanding of 6
Growth delivered (Del g)-10.0%+16.6%lowest of 6
Hurdle (Req g minus delivered)+3.5 pp+10.7 pp2nd least demanding of 6
ROIC minus cost of capital-64.5 pp-8.2 pplowest of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Chongqing Zhifei Biological Products 300122.SZChina$5.28B-1%-28%-210%5.3×-6.5%-10.0%
Anthem Biosciences ANTHEM.NSIndia$5.51B+16%-1%35%24.9×36.9%+26.2%
Caris Life Sciences CAIUnited States$5.59B+24%+61%13%5.0×18.2%+61.5%
Hangzhou Tigermed Consulting 300347.SZChina$4.88B-2%+16%10%4.8×25.9%+16.4%
Cogent Biosciences COGTUnited States$4.84B-16%n/an/an/an/an/a
Scholar Rock SRRKUnited States$5.86B-1%n/a-71,732%9,900.4×n/an/a
Dianthus Therapeutics DNTHUnited States$4.73B-5%-12%-8,684%1,432.1×n/an/a
Adaptive Biotechnologies ADPTUnited States$4.61B+104%+18%-16%15.8×n/an/a
Shanghai RAAS Blood Products 002252.SZChina$4.57B-15%-22%17%5.4×n/an/a
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%14.0×n/an/a
Edgewise Therapeutics EWTXUnited States$4.53B+26%n/an/an/an/an/a
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-1%2.8×32.4%+7.1%
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a
3SBio 1530.HKHong Kong$4.28B-31%+102%61%0.9×n/an/a
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%12.7×n/an/a
Immunovant IMVTUnited States$6.86B-7%n/an/an/an/an/a
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%8.0×n/an/a
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%1,000.7×n/an/a
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%95.6×n/an/a
10x Genomics TXGUnited States$7.51B+138%-4%-11%11.3×47.2%+16.6%

Questions

Who are Chongqing Zhifei Biological Products's main competitors?
Named competitors: Beijing Wantai Biological Pharmacy (603392.SS), Shenzhen Kangtai Biological Products (300601.SZ), Walvax Biotechnology (300142.SZ), Merck & Co (MRK). The cockpit's measured peer set (industry) also includes Anthem Biosciences (ANTHEM.NS), Caris Life Sciences (CAI), Hangzhou Tigermed Consulting (300347.SZ), Cogent Biosciences (COGT), Scholar Rock (SRRK), Dianthus Therapeutics (DNTH).
Is Chongqing Zhifei Biological Products expensive compared with its peers?
On ev / sales it trades at 5.3× against a peer median of 12.7×, 5th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is -10%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Chongqing Zhifei Biological Products stock performed?
Over six months to 18 Nov 2026 the shares returned -1.2% against -3.5% for the median peer; over one year -30.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.